

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 586 333 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
19.10.2005 Bulletin 2005/42

(51) Int Cl.7: A61K 45/06, A61P 35/00

(21) Application number: 05090011.7

(22) Date of filing: 20.06.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
LT LV RO SI

(30) Priority: 23.06.2000 EP 00250194
28.06.2000 EP 00250214(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
01965012.6 / 1 292 335(71) Applicant: Schering Aktiengesellschaft
13353 Berlin (DE)

(72) Inventors:
• Siemeister, Gerhard
13503 Berlin (DE)
• Haberey, Martin
12169 Berlin (DE)
• Thierauch, Karl-Heinz
14159 Berlin (DE)

Remarks:

This application was filed on 27 - 01 - 2005 as a divisional application to the application mentioned under INID code 62.

(54) Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF

receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.




Fig. 1

Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family.

The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

[0006] Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0007] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Gold-

man et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0008] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salven et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0009] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0010] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

[0011] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0012] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the

VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

5 (a) compounds which inhibit receptor tyrosine kinase activity,
 (b) compounds which inhibit ligand binding to receptors,
 (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 10 (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

15 [0013] A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented.

20 25 Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas exotoxin A*, *Diphtheria toxin*, or *Ricin A*. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domaines are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.

30 35 Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.

40 [0014] Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

45 [0015] Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

[0016] Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

5

10

15

20 in which

r

has the meaning of 0 to 2,


n

has the meaning of 0 to 2;

25

a) each independently from each other have the meaning of lower alkyl,


b) together form a bridge of general partial formula II,



I,

30

35



II,

40

wherein the binding is via the two terminal C-atoms, and


m

has the meaning of 0 to 4; or

45

c) together form a bridge of partial formula III

50



III,

55

wherein one or two of the ring members T1, T2, T3, T4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T1 and T4;

9 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa (-O-), thia (-S-) or imino (-NH-),

5 A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,

10 R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

15 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygene atom, or a salt thereof.

20 [0017] A preferred salt is the salt of an organic acid, especially a succinate.


[0018] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0019] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranyl acid derivatives of general formula IV

25

30

35



IV

40

in which


45 A has the meaning of group $=NR^2$,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,


Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group

50

55




or A, Z and R¹ together form the group



10

15


20



m, n and o	has the meaning of 0 - 3,
q	has the meaning of 1 - 6,
R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/ or R _b together with R _c and or R _d or R _c together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
X	has the meaning of group =NR ⁹ or =N-,
Y	has the meaning of group -(CH ₂) _p ,
p	has the meaning of integer 1-4,
R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
R ⁴ , R ⁵ , R ⁶ and R ⁷	independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or C ₁₋₆ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R ⁵ and R ⁶ together form the group

40


45



R ⁸ , R ⁹ and R ¹⁰	independently from each other have the meaning of hydrogen or C ₁₋₆ -alkyl, as well as their isomers and salts.
50 [0020]	These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.
[0021]	More preferentially compounds of genearal formula V

55

5




10

15


in which

80



30


35



40

in which R^5 is chloro, bromo or the group $-OCH_3$,


45



50

in which R^7 is $-CH_3$ or chloro,

55



in which R^8 is -CH₃, fluoro, chloro or -CF₃


in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

15

20 R^2 has the meaning of pyridyl or the group

25



and

30 R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

35 [0022] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0023] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

40 [0024] Claimed matter of the instant invention are therefor pharmaceutical compositions

45 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

50 b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

55 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of

the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

5 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

10 g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

15 h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

15 **[0025]** For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0026] The inventive compositions comprise as compound I or as compound II at least one of

20 a) compounds which inhibit receptor tyrosine kinase activity,

b) compounds which inhibit ligand binding to receptors,

c) compounds which inhibit activation of intracellular signal pathways of the receptors,

d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

25 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

30 **[0027]** Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

35 **[0028]** Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0029] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound

40 I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II

45 sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

50 **[0030]** The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerose, thromboc microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

55 The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

[0031] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also

possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0032] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGFNEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system.

[0035] Alternatively, combined functional interference with VEGFNEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGFNEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0036] The invention is also directed to a substance which functional interferes with both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems.

[0037] VEGFNEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiomyoma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thromboc microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase

inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-ANEGR receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

[0043] Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

[0044] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppi et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0045] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system, by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

[0046] The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

10

Example 3

15

[0047] Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

20

[0048] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

25

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

40

[0049] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

45

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-ANEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

50

Example 4

55

[0050] Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0051] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals re-

ceiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-ANEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

Table 4

mode of treatment		
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0052] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

[0053] The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGFNEGF receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

40

Example 5

[0054] Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

45

[0055] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

55

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0056] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

[0057] Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0058] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0059] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure

6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducting L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of 5 inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

[0060] The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

10

Description of the figures

[0061]

15

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

20

mock, con. = treatment group 1
 mock+VEGF-A = treatment group 2
 sTIE2-c113 = treatment group 3
 sTIE2-c113+VEGF-A = treatment group 4

25

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

30

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

35

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

40

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

45

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGFNEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

50

55

Sequence Identifier

<400> 2

5 gttctagatt gttttattca gtaattagct cttaaagaccc ctggggcctg tgctacccag 60
 acactaaca cagtctctat ccagttctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgaccc cgggagctat ttgcctgtt 180
 agtgcacaca cctggaaaca tactgctctc atttttcat ccacatcagt gagaaatgag 240
 tggcccgta gcaagatata actatgcaat catgcaacaa agctgcctaa taacattca 300
 ttttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 10 agttatagtg catabacagt tgattccat ttataaaggc agaaagtccct tgttttct 420
 aaatgtcaag ctttgactga aaactccgt ttttcagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatggagag aaggaaata gtacttgaaa tgtaggccct 540
 cacctccccca tgacatcctc catgagcctc ctgatgttagt g

<210> 3

<211> 516

<212> DNA

<213> Human

<400> 3

20 tagagatgtt gtttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagccaga catgtgcac tacatcacag aggacatgct catgtcgccg aacctgaatg 120
 gacactctgg gttgattgtt aaagaattt ggtttccac ctcgagctct tcagaacac 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcacat tgcaggatctg tgcaggaca ctgcctcagag ttacacctt ggtatgtggcc 360
 25 atgaactgga tgaggaaggc ctcttattgca acagttgctt ggcccagcag tgcataaca 420
 tccaagatgc ttttccagtc aaaagaacca gcaaatactt ttctctggat ctcactcatg 480
 atgaagtcc agagttgtt gtgtaaagtc cgtctg

<210> 4

<211> 1099

<212> DNA

<213> Human

<400> 4

30 cccacaacac agggggccctg aaacacgcca gcctctccctc tgggttcagc ttggccagg 60
 cctgctca gatcacacgc ccattgttagg tgggcattgg tggggatca ggcggcttgc 120
 35 ccacggggag gtagaagaag acctggcccg tggtaagggtc tgagaagggtg ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgcctca tccccggct gaggcagcga cacagcagg 240
 gcaccaactc cagcagggtt agcaccagg agatgagtc aaccaccaac atgaagatga 300
 tgaagatgtt ctctccgtg gggcgagaga caaaacgtc cagcaggtag gggcagggtg 360
 40 ctcgcgttgc cacaacacag ggctccatgg tccagccgtt caggcgcac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgcga gcacactggc gacatagggtt cccatcagt 480
 ctccgcggat ggcgcaggcga ccatcttctg ccaccgagat ttggccatc tgacgctta 540
 cggccgcccag cggccgcgtcc acctgtgggt cttggccgg cagtgcggcc agctccccct 600
 ccttctgcgtc cagccgtct ttcgcgcag acagtaaat gacatggccc agtagagacca 660
 45 ggggtgggtgt gtcgacgaaag aggaactgca gcacccagta gcccgttgc gggatggg 720
 aggcttgcgtc atagcagacat ttgggtgcagc ctggctggcc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactgcggc cagggccag gatgaggatg cggaaatg 840
 agagcaccgt cagccagatc ttacccacca cggcggccatg ctcctggacc tggccagca 900
 50 acttctccac gaagccccag tcacccatgg ctccggggcc tccgtcgccca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcacccatc tcgttcgccc agcaacaacg ctgcaggag 1020
 gtctgcacg cccgttctac cgcctgcctg ccggccggcc caggtggagg tggggacgat 1080
 ggcggaggc acgccccg

<210> 5

<211> 1015

<212> DNA

<213> Human

<400> 5

55 gaggataggg agcctggggc caggagtggtt ggagacacag cgagactctg tctccaaaaa 60

5 aaaaaagtgct ttttgaaaat gttgagggtt aaatgatggg aaccaacatt ctttgattt 120
 agtggggagc ataatacgaa acacccccc ggttcacaa tgcacaggaa tgggacccag 180
 ttggggcaca gccatggact tccccccctt ggaatgtgtg gtgcaaagt gggccaggc 240
 ccagacccaa gaggagaggg tggtcggcag acacccccc atgtcagcat ccccccacct 300
 gccttctggc ggcacctccc gggctgtgtt ttgagtcage aggcattgggg tgagagcctg 360
 gtatatgctg ggaacagggt gcaggggcca agcgttcctc cttcagccctt gacttggcc 420
 atgcacccccc tctcccccaa acacaaacaa gcacttctcc agtatggtgc caggacaggt 480
 gtcccttcag tcctctgtt atgacactaa gtccctacttg ggccttgcag cccagctgt 540
 gttgtaaacct ctgcgtccctc aagaccacac ctggaaagatt ttcttccctt ttgaaggaga 600
 atatcatttgc ttgttttata acttctaaaga cattttgtac ggcacggaca agttaaacag 660
 10 aatgtcttc cttccctggg gtctcacaacg ctccacag aatgcacacg gggccgtgca 720
 ctgggcaggc ttctctgtt aaccccgagg gttcggccc agaccacagc gtcttgcctt 780
 gagccctagag cagggagttc cgaacttctg cattcacaga ccacccacac aattgttata 840
 accaaaggcc tcctgttctt ttatccact taaatcaaca tgctattttt ttttcaactca 900
 ctctctgactt tagcctctgt ctgaggccgtg tatccatgca gtcatgttca cgtgcttagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa
 15 <210> 6
 <211> 2313
 <212> DNA
 <213> Human
 20 <400> 6
 ccagagcagg cctgggtggg agcaggacg gtgcacccga cggcgggatc gagcaaatgg 60
 gtctggccat ggagcacgga gggcttacg ctcggccggg gggcagctt cggggctgtct 120
 ggtattacct gcgctacttc ttcccttcg tcccttcat ccaatttcctt atcatcttgg 180
 ggctcgtct cttcatggc tatggcaacg tgcacgttag cacagagtcc aacctgcagg 240
 25 ccaccgagcg ccgagccgag ggcctataca gtcaagtcctt agggctcaag gcctcccaagt 300
 ccaacttgcac caaggagctc aacttcacca cccgcgcacca ggtgcacatc atgcagatgt 360
 ggctgaatgc tcgcccgcac ctggaccgca tcaatgcacccat cttccgcac tgccagggt 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatctt agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaaca agatgtcgaa tgcccttgc ttcatgtca 540
 atcagaaggt gaagacgtg gagggtggaga tagccaaggaa gaagaccatt tgcaactaagg 600
 ataaggaaag cgtgtctgt aacaaacgcg tggcgaggaa acagctgggtt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgc acttggcaag gagcaactgc aaaaggtgca 720
 agccctctgc ctggccctgg acaaggacaa gtttgcgtt gacccctcgta acctgtggag 780
 ggacttcatt atcccacgca gcttgcgacaa ccttgggttac aaccccttacc atcccttggg 840
 ctcggattt gcctccatcc gcaagcgttgc cggccatcatc cccagcttca tgagctccaa 900
 ggtggaggag ctggcccgga gcctccggc ggatatcgaa cgcgtggccc gcgagaactc 960
 35 agacctccaa cgccagaagc tggaaagccca gcaggccctg cggccagtc aggaggcgaa 1020
 acagaaggtg gagaaggagg ctcaaggcccg ggaggccaaatccttgc tccaaagctt aatgcctcccg 1080
 gcagacccag ctgcgtcttgg aggagaaggc ggtgtctgcgg aaggaacgag acaacccgtgc 1140
 caaggagctg gaagagaaga agaggaggc ggagcagtc aggtggagc tggccatcag 1200
 aaactcagcc ctggacacccat gcatcaacaaac caatgcgtcg ccatgtatgc cagtgtcaag 1260
 40 gcccatgggc cctgttccca acccccgcc catcgaccatc gctagcttgg aggaggctaa 1320
 gaggaaagatc ctggagtcccccc agaggcccccc tgcaggcatc cctgttagccc catccagtgg 1380
 ctgaggaggc tccaggcctt aggaccaagg gatggcccgatc ctggcggtt tgccggaggat 1440
 gcagggatat gtcacacgc cccgacacaa cccctcccg ccccccacca ccacccagg 1500
 ccacccatcag acaactccctt gcatgcaaaac cccttagtacc ctctcacacc cgcacccgc 1560
 cctcacatcgc cctccatcccg agcacacgcg cggccatgtt acgttcacgc acaacccgc 1620
 ctgacgttcat atatccatcgtt ggtgtatggc tcacgtggcc atgttagacgt cacgaagaga 1680
 45 tatacgatc gcgtcgatc gatgcacac gtcgcacaca gacatggggaa acttggcatg 1740
 acgtcacacc gagatgcacgc aacgcacgtca cggccatgtt cgacgttccatcataatg 1800
 tcacacagac gccgcgttgg catcacacag acgggtatgtt tgacacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacccatata gatatggcac caacatcaca tgacacgtatc 1920
 cccttccaca cacaacttttccatc acccaatttccatc caccatgtt gacatggggaa cggcccttggc 1980
 acacggggccaa aggttacccatc aggatcccat cccctcccgcc acagccctgg gccccagcac 2040
 50 ctcccttcctt ccagttccatc ggcctcccgcc ccaatcccttccatc acccccccgtt cctggacccg 2100
 gaggtgagaa caggaagccaa ttcaccccttgc ctccttgcgtt gtaggtttt ccaggaccc 2160
 ctggggggccctt ttagccgggggg gtaggggtca cctgttgcgtt ggagggggac cactcccttctt 2220
 cccccaactc ccacggccatc ctgtggcccg ttggaaatgtt ggtggcactt aataaatattt 2280
 agttaaatccatc taaaaaaaaaaa aaaaaaaaaaaa aaa
 55 <210> 7
 <211> 389

<212> DNA
<213> Human

<400> 7

```
gccaaaaga tggctcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaatag aagaccttgc 120
tattctaaaa tcagatccctt acagatccag atttcagaa acaaatacat aggggactaa 180
ctttccctgt tcagattgtt ttttccctt tgcccccagc tatataatat gggaaatgtat 240
tgacttttaaa aaggttttggt agttttccat ttttttgtata tgaaaatgtt tattttcggtt 300
gaacctgtag ctatataaa tctatgtggc tagtgcgtat atatttgcgtt gaattttgttc 360
tccttttgtt gtgtccagtg ggtaacatc
```

<210> 8

<211> 157

<212> DNA

<213> Human

<400> 8

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt gttttgttag 60
gaagcagggaa gcaaggccac tcaaactgtga aattttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatata tggatgttga tattttg

<210> 9

<211> 561

<212> DNA

<213> Human

<400> 9

aatagtcaaa	acataaaacaa	aagctaatta	actggcactg	ttgtcacctg	agactaagtg	60
gatgttgg	gctgacatac	aggctcagcc	agcagagaaa	gaattctgaa	ttcccttgc	120
tgaactgaac	tattctgtt	catatggtt	acaaatctgt	gtgttattt	ttttctacct	180
accatattt	aatttatgag	tatcaaccga	ggacatagtc	aaaccccgta	tgtatgaacat	240
tccgtattt	ttgcctgtt	aatctctgtt	gagctctact	tgtggtcatt	caagattttt	300
tgtatgttggaa	aggaaaaatgt	aattatgcct	ttaaaaattt	tatttttgggt	gatgtatgtc	360
tccaccat	aaaactgtca	attattgcct	aatgttaaaag	atatccatca	ttgttattaa	420
ttaaacctt	aataggattt	cttaatggag	aatttctaatt	ggatggattt	tcccccgtatc	480
ttttctttaa	aatttctctg	cacacacagg	acttcttcatt	ttcccaataaa	tgggtgtact	540
ctggcccaat	ttcttaggaaa	a				

<210> 10

<211> 1508

<212> DNA

<213> Human

<400> 10

cacaacacg	agagactcca	cggtctgcct	gaggaccgc	agccctcctag	gtccagcac	60
tgcgagggtcc	attcttctgc	acgagccct	ctgtccagat	ccataagcac	gtcagctca	120
gggtcgccga	gcagtagcgg	gacaagtacc	agcagcagct	cctctgaaca	gagactgcta	180
ggatcatcc	tctccctccgg	gcccgttgc	gatggcataa	tccgggtgca	acccaaatct	240
gagctcaagc	cagggtggact	taagccact	agcaaggaa	atttgggcct	gcacgcctac	300
agggtgtgagg	actgtggaa	gtcaaaatgt	aaggagtgc	cctacccaa	gcctctggca	360
tcaagactgg	tctgcgacaa	gcaagtgcct	tgctcgccc	aaacacgtat	tgactatgg	420
acttgtgtat	gctgtgtgaa	aggtcttc	tatcactgtt	ctaataatgt	tgaggacaac	480
tgtgctgaca	acccatgttc	ttgcagccag	tctcactgtt	gtacacgtg	gtcagccatg	540
gggtgtcatgt	ccctttttt	gccttggta	tgggttacc	ttccagccaa	gggttgccct	600
aaatttgtgcc	aggggtgtta	tgaccgggtt	aacaggctg	gttggccgtg	taaaaaactca	660
aacacagttt	gctgcaaaagt	tcccactgtc	ccccctagga	actttgaaaa	accaacatag	720
catcattaat	caggaaat	acagatata	ggatttttc	ttttttttt	taataacacat	780
atgcaaccaa	ctaaacagtt	ataatctgg	cactgttaat	agaaatgtt	gatagtctt	840
gctgtttgcg	gtaaatgt	tttgcgtt	gtgcccgtt	aactgtat	cttggtagaa	900
ctcagctaat	ggagctcaaa	gtatgagata	cagaacttgg	tgaccatgt	attgcataag	960
ctaaagcaac	acagacactc	ctaggccaaag	ttttgttt	tgaatagtac	ttgcaaaaact	1020

EP 1 586 333 A2

<211> 1002
<212> DNA
<213> Human

<400> 14

gacaatataa	aaagtggaaa	caagcataaa	ttgcagacat	aaaataatct	tctggtagaa	60
acagttgtgg	agaacaggtt	gagtagagca	acaacaacaa	aagcttatgc	agtcaccc	120
tttggaaatg	ttaaatacaa	gtcctattct	ctttgtccag	ctgggtttag	ctagaggtag	180
ccaattactt	ctcttaaggt	ccatggcatt	cgcaggatt	ctataaaagc	caagttact	240
gaagttaaata	tctggggccc	atcgcccccc	cactaagtgac	tttgcacca	tgttgtatct	300
taaaagtcat	ttttcaactgt	ttgactcaga	atttgggact	tcaagtcac	acttcattgc	360
ttaactccaa	cccaggttaa	tttccccactt	tttaaagttag	gcttagctt	gagtgatttt	420
tggctataac	cgaaatgtaa	atccaccc	aaacaacaaa	gtttgacaag	actgaaaatgt	480
tactgaaaac	aatggtgcca	tatgctccaa	agacattttc	ccaagataac	tgccaaagag	540
tttttgagga	ggacaatgtat	catttattat	gttaggagct	tgatatctct	gcaaaataga	600
attaataacag	ctcaaatgg	gttagtaacca	agctttctg	cccagaagtt	aacaaacatc	660
actacgaaca	tgagagtaca	agaggaaact	ttcataatgc	attttttcat	tcatacatcc	720
attaataaaa	cattagccaa	gttaatgtcc	caagccactg	tgccaggat	taacaatata	780
acaaaataaa	aagacacagt	ctttcctctc	aagggttca	gtcttaggg	gaagatgatt	840
attcattaaaa	atttttgggt	catcagaatc	atgaggagct	tgtcaaaaat	gttaattct	900
gcctatgttc	tcaagatattc	tggtaggtc	aggagtggga	accaaaaatc	aattctttta	960
acaaaacacta	aagggtgatc	taacacagggc	ggtgtgagga	cc		

<210> 15

<211> 280

<212> DNA

<213> Human

<400> 15

```
cgaggtggc caccgtgtc tggctctgaga tttttaaatg aggattacat tatcctattt 60
ataatattcc tatttcaata tattgttattt ttacaattaa atgtatcaaa taattcttaa 120
aaacattattt agaaacaaac tgccctaatac cttataagac taaaaaaatc accaagatga 180
aactgttatac tgactctcaa tattttaaca tttttttttt tttttttttt 240
caatcttaac tatttcacctt gccccggcggttccgctcgagg
```

<210> 16

<211> 2041

<212> DNA

<213> Human

<400> .16

ccccccgcag aactcccccc tgaatagga tttttaaac ccttgcacat tagaaatcc 60
atagaggta gcattttta ggtaaaaata tggttgcccc tacagggatc atgcacttc 120
cttaaaacca attcagcaca tatgtataaa gaacccttt taaaacatt tgtaactgaa 180
atacagacac agtgatgctg aagacactaa aaaaaactg aaaagacta taccttgata 240
aattttgtta ttgccttctt tagagactt taaatctca gttgatttc aaggacttga 300
attnaataat gggtaattt cacaagacgt aaaggattt tttaaaacaa gtattttttt 360
ttacctctag catcaatttct ttataaaaga atgctaaata aattacattt ttgttcagt 420
aaaactgaag atagaccatt taaatgttc taccaaattt aacgcagctt aatttagggac 480
caggtacata ttgccttctg aacatttttgc gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaaag aggttagattt ttgccttgc aatgcattttg ttaataatg tgcaagaaaa 600
ataaaaaacaac gcaactgatg tggctcttgc aagtataagg gtctaatgaa aaataaaaaga 660
tagatatttgc ttatagtcg acattttaac agtcatagta tttagacgtt cgtgaccagt 720
gcattttgttgc ctctctcagg atcaaaaatc gatgtgcgcactgttataatccctcc 780
accccccctcca ccagttggtc cacagcttcc tggggggctcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagtttgc tatagcatcc ataaggctt tctgttagagg 900
ttcctgtaaa tatagtttat tggctttgttgc ttatccca gtcactggat ggggttataatccctcc 960
tgggtctcca ttatccca gtcactggat atgcgtttt tttatcccaaa gacataagg cactaaac cattagttact 1020
atgcgtttt tttatcccaaa gacataagg tgggttataatccctcc 1080
tctggactgac tggaaatgaaatgac tttatcccaaa gacataagg tgggttataatccctcc 1140
tttgacatttc ttatcccaaa gacataagg tttatcccaaa gacataagg tgggttataatccctcc 1200
gtaaaatgact ctggggaggat gctaatgcca aaaaaatgcactgttacttgcacttgc 1260
aagagtcgttacttgcata ttgcctccata gggctcaga ctgggttac atctgtatgttacttgcacttgc 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtccc tgaaggctt aattttttag caaggttctc actaagatca gtgaagtc当地 1440
 catctacaga ccaactttct gacaatgaag agaaaagaatg aattttctca actggcaact 1500
 cccaaaaccag tgccagtgta tacatgtct aaaatttcc ttctcacatg atacttctga 1560
 tcataatggaa attcctaggag agtaagaata aggtatttc当地 gttcctccgt gatttgcat 1620
 gtttttc当地 cattttc当地 agaggcacag tttcacaat aatattgggtt atcaccatg 1680
 agaactctcg gagcccaaaa aataattttg taatgtc当地 actgaaggtg tggttcacc 1740
 tcccggttcc tgaggtacat ctttattaa aagaatctt tagattc当地 tagggacac 1800
 agtgtttca gaacagtaaa actcatttgg aggactgc当地 atggttttt cattcacaa 1860
 tgagtacag atgaaggcag ctgtgttgg attataaact actggcttcc ctgaaggacc 1920
 gggtagcagac gtttgc当地 gaccaccatc ttgtatactg ggtgatgtg ctggatctt 1980
 gacagacatg tttccaaag aagaggaacg acaaaccgc当地 agcggaaatg ctgtaaaggc 2040
 t

 <210> 17
 <211> 235
 <212> DNA
 <213> Human

 <400> 17

 20 cccccccggc aggtgtcagg ggttccaaac cagccctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtc当地 120
 agataactcg gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180
 tggccacga tcatgtc当地 acactccagc ttgggtgaca aaatgagact gtcta

 <210> 18
 <211> 2732
 <212> DNA
 <213> Human

 <400> 18

 30 gtgtggagtt tcagctgctt ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttcat aactactttt tagggc当地 cattggaccc ttatctctc当地 120
 aaatattatc ttcttggta tcacatttg caaaatggg aacgattca acactttgaa 180
 accagattct agcagggtgg aaaaacattaa gtcttgggtt cttggc当地 tcgcttctt 240
 gtgtcttctt ggccctc当地 ggtcctttgg gttgc当地 attaatggg agactattgt 300
 gatggcatat ctottc当地 tatttaatgc ttccaggga gtgttc当地 tcatcttca 360
 ctgtctctc当地 caaaagaaaag tacgaaaaga atatggcaag tgcttc当地 actcataactg 420
 ctgtggggc cttccaaactg agatgtccca cagttc当地 aaggcatcaa ccaccaggaa 480
 ctagtgc当地 tatttcttgg gagaaaaacaatc tcaaatctt tttttatctc aggtgacatc aatagactt caacactt当地 600
 tcaagggtggc ataaatctt catcttcaag atttatatca ttttagaggac attcaactgaa caatgccagg tctggagggc 660
 ccatggatac tctaccgctt aatggtaatt ttaacaacag ctactcgctg cacaagggtg 720
 actataatga cagcgtgca gttgtggact gtggactaag tctgaatgtat actgtttt 840
 agaaaaatgt catttc当地 tttagtgc当地 acaacttacg gggcagc当地 aagactc当地 900
 acctcgagct cagcttccatc gtcaaaacttgg tgatttgggg tagcagc当地 gaagatgtg 960
 ctatgtggc agatgtcttctt cttttatgc acagc当地 cccagggtg gagctcc当地 1020
 acaaagaact cgaggccatc cttatttctc agcggactca ctcccttctg taccacccc 1080
 agaagaaaatgt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccccc aacagagact ctcttatac aagcatgccc aatctttagag 1200
 actctccctt tccggagagc agccctgaca tgaaagaaga cctctctccc tccaggagga 1260
 gtgagaatga ggacatttac tataaaaatgc tgccaaatct tggagctggc catcagctc 1320
 agatgtctt ccaagatc当地 aggggcaata ggtgatgttataatcccc attaacaatg 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaaat gcagctggg acaagtc当地 1440
 aatcatacag ctaaggaaatt ccaagggccatc catcgacta ttataaaaatgc aacagccat 1500
 tggcctgacg cagctccctt aaactctctt gtaagagatg actcttgc当地 tttgttctc 1560
 tgggttaaaa aagatgtactg aaccttgc当地 ttctgtgaat ttttataaaa catacaaaa 1620
 ctttgtatatac acacagatg tactaaatgt aatttttgc当地 tacaagaaa agagatgcca 1680
 gccagggtatt ttaaggtct gctgtgtt当地 agagaatgtg tgaaacaatg aaaacaaaac 1740
 tttccagcca tttactgtca gcagttctg aactaaatgt gtaatatgg ctgc当地 1800
 tttttagggcc tgc当地 tttatataca agcttaggtt taaaatctg tggggacaaa 1860
 ttactgttacc ttacttattcc tgacaagact tgaaaagca ggagagatg ctgc当地 1920
 tttgc当地 actgcaaaatc ttttacattt当地 agccaaatg tgaaaacatg cttaccact 1980

ctgtgattgc tgactacttt ggcagagggtg tttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggtgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcaactaa gcagcctgg aagaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatggacc tggcggcgtt ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaagt cacagccctc acaagactaa agcggaaactt tttctttcc 2220
 ctgccttcc ttaattttaa gtcaagctt gcaatccctt cctcttaac taggcagggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaaccc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

 <210> 21
 10 <211> 179
 <212> DNA
 <213> Human

 <400> 21

 15 aggtgttaga tgctcttgaaa aaaaactg catctaagt gtcagaaaatg gattctttt 60
 acaatcaact aaaggaactg agagaaaacct acaacacaca gcagttagcc cttgaacagc 120
 ttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

 <210> 22
 20 <211> 905
 <212> DNA
 <213> Human

 <400> 22

 25 tttttttttt ttctttaacc gtgtggctt tatttcagtg ccagtgttac agataacaaca 60
 caaatgttcc agttagaagg aattcaaaacg gaatgccaag gtccaaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaaggg 180
 caaaggtaact tttgatcacag agtctgtatct ttggaaactgg tgaactccctc ttccacccat 240
 taccatagtt caaacaggca agttatggc tttaggacac tttaaaaattt gtgggtggaa 300
 tagggtcatt aataactatg aatatatctt tttagggtt accattttc actttaaagg 360
 gaatcaattt taaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaaag 420
 30 gggagctgga agagccttgg aagtttctat tacaatataa gcaccatatac ttccatgcca 480
 aactctcaaca aaagctttt ttaactccat ctgtccagtg ttacaaaata aactcgaag 540
 gtcgtaccag ttcttggtaa caaacatatac tttttttttt ttccatgtc ttgtgtgtata cagcaatgca 600
 cagaaaaaggc taccaggagc ctaatgcctc ttccaaacat tgggggaacc agtagaaaaa 660
 ggcagggctc ctaatgtcc attattacat ttccatgtc aatggccatgt tttaaaagt 720
 35 ccttgaatgtt gtaaccccgat tagtggaaa taaaatcccc accttgcctt gtccacagag 780
 aaacaacagt agaaaagaagg ggcaactt tttttttttt ttccatgtc ttgtgtgtata 840
 ccatggattt cagtccctctc ttccatgtc ttccatgtc ttgtgtgtata ttccatgtc ttgtgtgtata 900
 gttga

 <210> 23
 40 <211> 2134
 <212> DNA
 <213> Human

 <400> 23

 45 ggtctcttct ttctttttttt tttttccaaa agtggctttt tattttttttt aacatataatt 60
 gtataaaatac tctattttat atgcacttcc aaaaaaggcgataataatataa aagttttttt 120
 cattagaaaat aaatgtataa aaataatataat gttttatataa gttttatataa ctaactatag 180
 tccttcttgg aaggaacacc caaaccataa ctatataatgtt atatgttataa tataatgttataa 240
 tattttacta tataatataatgtt gaaaaatca tattttttttt tttttttttt tttttttttt 300
 accaggatac gactgttggc ccagctgttcc gagatggacc tttttttttt tttttttttt 360
 cccaccacaa gacaagtgtat ctcaatgtcc ccaaaacctgtt gggaccctgtt tttttttttt 420
 50 tcattttttttt tccggcggtt catcccttccatgtt gttttttttt tttttttttt tttttttttt 480
 agttacttctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 tggaggtaact aagcttccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660
 aaatgttataa cacaatataa gactgttccat tttttttttt tttttttttt tttttttttt tttttttttt 720
 55 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
 tagaaaataat gtataaaatcat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 840
 atccatgttccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 900

taaaatctca cttttctcct actttcatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacagggggt tgaatagtt ctaacttttt ttgacaattt ctttgggttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
 tgctatatac ctgctcagag gttataatc ctcataact atcctatcaa atttgcact 1140
 ggcatgttac tctgtatgatt caactccctt tctatctacc cccataatcc caccttactg 1200
 atacacccca ctggttactg gcaagatatacg ctgatccct ccagccttct tgctttccct 1260
 gcaccagccc ttccctcactt tgccttgcct tcaaaagctaa caccacttaa accacttaac 1320
 tgcatctgc cattgtgcaa aagtctatga aatgtttagg ttctttaaa ggatcacacg 1380
 tctcatgaga taacaccctt ccacatcatggg acagacactt caagcttctt tttttgtaa 1440
 ccttcccaca ggtcttagaa catgtatggc actcccccag ctgcccactgg gggcaggat 1500
 ggtctgcaca aggtctgggt ctggctggct tcacttccct tgccacactcg gaagcaggct 1560
 gtcattaaat gtctcggcat tctaccatgc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgaccatcg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt cttaacaaat taggtgtttaaatttttagg tcgaagggca ttgcccacag 1740
 taagaacactg gatggtcaag ggcttttga gagggtctaa gctgcgaatt ctttccaatg 1800
 cccgagagga gcccgtgtac ctcaagacaa cacccttgcataatgtct tgctctaagg 1860
 tggacaaatgt gtatgtccacca ttaagaatat atgtccatc agcagcttgc atggcaagaa 1920
 agctgcattt gttccctggat cccctgttgc tccgctgtt cacttcgttgc ttggctggctc 1980
 cagttggaaat tttgtatgata tcatgtatc cagtttgc acttagtaact gatctgtata 2040
 ttttttaca agtagatcca ttccccccgc aaacaccaca ttatcaaac ttcttttgg 2100
 agtctatgtatgcgatcacaa ccagcttttca caca

 20 <210> 24
 <211> 1626
 <212> DNA
 <213> Human

 25 <400> 24

 ggacaatttc tagaatctat agtagtatca ggatataattt tgctttaaa tatattttgg 60
 ttatatttgaa tacagacattt ggctccaaat tttcatcttt gcacaatagt atgactttt 120
 actagaactt ctcacacattt gggaaacttgc caaatatgatg catcatatgt gttaaaggctg 180
 tatacattaa tgcataatgaa tacattttt tctccctatg cccaaacagggt gaacaaacgt 240
 agttgtttt tactgtatctt aaatgttgc tacctgtat tttatagtttgc acatgtca 300
 gaaaaaggca agacaaatgg cctcttgc tgaataactt ggcaaaacttta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttttagatc ttgcgttagaa tggattacat 420
 ggtatgtatc cactgttgc aatggttttt agttattgtatc tccatgttgc tctcaggatg 480
 aatctttat gtcctttat tgcataatgaa tctgtatgttgc attttgcgttgc tccatgttgc 540
 aaagctttgt ctaaaaattt ggccttagaa tggtaacttgc attttgcgttgc tccatgttgc 600
 agaaaaataaa tatgtgttgc tttatgttgc tttatgttgc tccatgttgc tccatgttgc 660
 atgtattttaa atattttca tattctgttgc caagcatttta taatttgcgttgc tccatgttgc 720
 ccattttagcc cagtgggaaa gtcttggaaac tcagggttacc cttgttgcgttgc tccatgttgc 780
 ccatctctttt gatctgttgc taaactgttgc tttatgttgc tccatgttgc tccatgttgc 840
 tctggatgc attagttatc ccttgcgttgc tttatgttgc tccatgttgc tccatgttgc 900
 ggtatgtatc tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 960
 atcttaacta actggtcctc aactcaagca gagtttcttgc actctggcacttgc tttatgttgc 1020
 aaacttagta gagggggattt tttatgttgc tccatgttgc tccatgttgc tccatgttgc 1080
 taaaattctt aaagagcaaa actgcattttt atttctgtatc cccatcttgc tccatgttgc 1140
 aactaagata ttatctatgaaatataa tttatgttgc tccatgttgc tccatgttgc 1200
 cgttggatgc tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1260
 atggattttt ctatagctaa atggatccc tttatgttgc tccatgttgc tccatgttgc 1320
 atggcaggatc tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1380
 tttatgttgc tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1440
 tttatgttgc tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1500
 attatacctg tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1560
 tacttggaaa tttatgttgc tccatgttgc tccatgttgc tccatgttgc tccatgttgc 1620
 aaaaaaa

 50 <210> 25
 <211> 1420
 <212> DNA
 <213> Human

 55 <400> 25

 gttcaggcatt gtttctgctt ctgaaatctg tttatgttgc tccatgttgc tccatgttgc 60

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgttctg acgggttggc tgctggggg ctttccccctc actgtcattt gaggcattt 120
 tggagaac aacggccagcc cctttatgc accctgtcg accaagaaca tcgccccgg 180
 gattccaccc cagccctggt acaagttac tgcattccac atgactgtt gaggcttcct 240
 gccttcagt gccatctctg tggagctgtt ctacatctt gccacagtat ggggtcg 300
 gcagttactt ttgtacggca tcctcttctt tgcattcgcc atcctgtca tggtggggc 360
 ttgcattctcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtgt 420
 gcatctgtg ctgagtgtt gctccaccgg cctttatcc ttcctctact cagtttcta 480
 ttatcccgg cgctccaaca tgcattggggc agtacagaca gtagagttct tcggctactc 540
 cttaactact gtttatgtct tcttcctcat gtcggcacc atcctctttt tttcttcct 600
 aaagtccatc cggatattatc atgttaacct caagatggac tgatgttgc atggcagaac 660
 tattgtgtt ctctccctt ctcatgccc tggtgactc tcctaccagg ttctttctg 720
 attgactgaa ttgtgtgtatg gcatgttgc ctccctttt tcccttggg cattccctcc 780
 ccagagaggg cctggaaatt ataaatctt atcacataag gattatataat ttgaactttt 840
 taagttgcct ttagtttgg tcctgatttt tcttttaca attacaaaaa taaaatttat 900
 15 taagaaaaag aaaaaaaaaa aaaaaaaaaa
 ~
 <210> 29
 <211> 1775
 <212> DNA
 <213> Human
 20 <400> 29
 gaacgtgtatg ggaactttgg gaggatgtct gaaaaatgt ccgaaggat tttggccaac 60
 accagaaaaac gcaatgtcc taggaattcc ctcccaaaat gttcccaaa aaattactca 120
 25 ttgacaattc aatttgact tggctggggc cagccggggc ggccttcagt ccgtgtggg 180
 cggcccggtg gccttcctcgt cgttggactc cccaaactcg ttcactctgc gtttattccac 240
 aggataaaac caccgtgtt acaggtagac cagaacacc acgtcgccccc ggaagcaggc 300
 cagccgggtga gacgtggggca tggtgtatg gaaggcaag acgtcatcaa tgaagggttt 360
 gaaaggccatg taggtgtaaagg cttccaggg catgtgtcc actgttagtt acttggtagtt 420
 cacaagagc tggggcaga tgaaggaa accaaaggca tagaccggc tgacgaagct 480
 30 gttgatatac caggagttacc agtcttata tttgtatattc aggagtgaat agacagcacc 540
 cccgacacag agagggtaa gcaaggatgtca caagtacttc atggcctgag ttcgttactc 600
 ctccgttttc ctctcagatt cgcgttaatg gccaaactga aattcgggca tcaggctct 660
 ccaaaaaata gtcatcttca atgccttctt cacttccac agctcaatgg cggctccaac 720
 accccgggg accagcacca gcaaggctgt ctgtcgcc acgaggaaaca gaaagatgac 780
 caccgtgtg aacgacgcgc agacgttcg cttggggac atggcgtatc tgctcttctt 840
 35 ctcttccatg aaactgtatg cattttaaa ggcggaaa tcaagagaa gatggacgc 900
 tgcacaaag aaggtcagcg ccaggaaatgta taatgggtt tctacaaaaa ttcccttcac 960
 ctcatcagca tctttctctg aaaaccggaa ctgtcgagg gaggatcacgg cgtcctgcat 1020
 gtggatccatg aacgcgcagcc gccccagtga gaccttgcg taggacacgg tgaggggcag 1080
 ctcgggtgtg gaggcggtta tgaccatcg gtccttcacg cgggtgtctga gctgggtcgat 1140
 gaacaggatg ggcaggatgt gcacgggttt cccaggctgg atcatcttca tgcgttccat 1200
 40 cacaatggca ggcaggggagg aaccgtcaaa gacaaatgtt tccggccatca cgttcagcgc 1260
 cagccgggtt cggccagggtt acactgttc atccaggcga ctgcgtcggt tcttctccgc 1320
 ctcgatctgc tggatgtatcg actccccgtt gagcagggtt atttcttctg gcttggggac 1380
 catgttaggtg gtcagaggac tgaccagggtt cacatgttc cgcgtcgcc acggcaggac 1440
 cccagcgtga tggaggaaatg tgtaggtata cagcgtccca tgggttctcg ttttcttgg 1500
 tacagaaaaaca ttaactgtcc ttcaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggatcg atgtgtttc cagcaggccatc gttggacatc gtcgtgtgtt acacgttcag 1620
 45 ctgcgttgc gggccggcccg ccaggatggg ctggatgtc tggtggccgc cggagcacgg 1680
 gcccgggtgtatg acgtggccgtt acatgacccca gcaaggatgtc accacgttgcg ccacgaacac 1740
 gcccaccacc aagctgggtga aggagctgcg gcccc
 <210> 30
 <211> 1546
 50 <212> DNA
 <213> Human
 <400> 30
 aaaataagta ggaatggca gtgggtattc acattcacta cacctttcc atttgctaat 60
 55 aaggccctgc caggctggga gggaaatgtc cctgcctgct tctggagaaa gaagatattt 120

acaccatcta	cgggacccat	ggaaactgctt	caagtgcacca	ttctttttct	tctgcccagt	180
atttgcagca	gtaacagcac	aggtgttta	gaggcagcta	ataattcact	tgttgttact	240
acaacaaaac	catctataac	aacacccaaac	acagaatcat	tacagaaaaaa	tgttgtcaca	300
ccaacaactg	gaacaactcc	taaaggaaaca	atcaccaatg	aattacttaa	aatgtctctg	360
atgtcaacag	ctactttttt	aacaagttaaa	gatgaaggat	tgaagccac	aaccactgtat	420
gtcaggagaag	atgactccat	cattcaaaac	gtaacagtaa	caagtgttac	acttccaaat	480
gctgtttcaa	cattacaaatg	ttccaaaccc	aagactgaaa	ctcagagttc	attaaaaca	540
acagaaatac	caggtagtgt	tctacaacca	gatgcacatc	ctctaaaac	tggtatcac	600
acctcaatac	cagttaaat	tccagaaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
ggtggaaaaaa	atgcaagcac	ttcagcaacc	agccggctt	attccagttat	tattttgcgg	720
gtggttattt	ctttgattgt	aataacactt	tcagttttt	ttctgttggg	tttgttaccga	780
atgtgttgg	aggcagatcc	gggcacacca	gaaaatgaa	atgatcaacc	tcagtcgtat	840
aaagagagcg	tgaagtttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactt	900
gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaatct	ctccacacct	aggcataataat	960
tacgcttaat	cttcagctt	tatgcaccaa	gcgtggaaaa	ggagaaaatgc	ctgcagaatc	1020
aatcccgact	tccatacttgc	ctgtctggact	gtaccagacg	tctgtcccag	ttaaagtgtat	1080
tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
tcacatttaa	aaattccatt	actccattta	caggagcgtt	ccttagggaaaa	ggaatttttag	1200
gaggagaatt	tgtgacgact	gaatctgaca	gcccaggagg	tgggtctcgct	gataggcattg	1260
actttcccta	atgtttaaag	tttccgggc	caagaatttt	tatccatgaa	gactttccata	1320
cttttctcgg	tgttcttata	ttaacctactg	tttagtattta	ttgttacca	ctatgttaat	1380
gcaggggaaaa	gttgacgtg	tattttaaa	tatttaggtag	aaatcataacc	atgtctactt	1440
gtatcataata	gtatttttt	cctgtttctg	tgttacttt	ataataataac	tactgttactc	1500
aataactctaa	aaatactata	acatgactgt	aaaaatqca	aaaaaaa		

<210> 31
<211> 750
<212> DNA
<213> Human

<400> 31

```

cacttggcca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtctg 60
aagggaagtg cctctgatgg cccaaaaacc ttttccaaa ctagtgtagg aatggaatgg 120
atagcaaatg gatccccccc ggcctccctt ggagcatgcc ttcccttatct tatccttggc 180
cccactaaag cagaacgcta cgatatttc tgaaaaatggc attggatgcc tatctggcca 240
aacagcctt ccctaattgg aaaaatgcgt cttttttttt acctttgtt tacgactact 300
tgtatcatgt tgctcattac aattttgaca tttttttatcatgtt acgttggatcc 360
cagtggaaaca tgacaagatc ataaaagaaca gtatcatatt attattttgtt cgttttttaca 420
gtggcaagcc aattttgaaa tatctcattt aaaaactcaga cccaaattcac tgagttatac 480
tttaataatg ttccttcagca cactatattcc catgcattaa atatgataaa ataatctatc 540
actggcccatc ggtctgtaa aaaaaggatc tgaatacaga gcccacaaca cttaaaattgt 600
ttttctagct acaaaggatata gcatcatcaa cacagacacg atttggactc cttgacaggt 660
ggatggaaac acgggttta aagagaagag aacattttaa cataaatgtc attaagaatc 720
ccaaaggct tattttgtcac caccgtcccc

```

<210> 32
<211> 1620
<212> DNA
<213> Human

<400> 32

5
agctgcgttg tgtgaaacca tgggtaaaaa gcacagctgg ctgcgtttta ctgcttgt 2700
agtacgagt ccattgtaat catcacattt ctaaaccaaa ctaccaataa agaaaacaga 2760
catccaccag taagcaagct ctgttagct tccatggta gtggtagctt ctctccacca 2820
agtgtccctc cttagacaag gaattatctt aacaactaa actatccatc acactaccc 2880
ggtatgcccac caccctggta acatggag attttataca ttaatctgat ctgtttaatc 2940
tgatcggtt agtagagatt ttatacat

<210> 34

<211> 6011

<212> DNA

10 <213> Human

<400> 34

15

acggggcgcc ggacgaccgg cacatcttat cctccacgcc ccactcgcac tcggagcg 60
accggcccg actccccctc gggccggca ctcgaggagt gaggagagag gcccggcc 120
cggttgagc cgagcgcagc acccccccg ccccgccca gaattttgtt tgaaccggc 180
tgccggaga aactttttt tttttttttt ctetcccg 240
ggaactcccc cggcccaagg ctcgtggct cgggtcg 300
tccggcccg aggggaggcg cccccgggaa cccgagaggg ggttgaggac cgcgggctgc 360
tggtgccggcg gggcgacgt gtggcccg caggggaggg gcccggccgc tccggcccg 420
gctcgagga ggaggcgccg gggcgccagg agatgtact ttgtggcg 480
ttggccggct gccccccaccc cctggtctcg ctgtggggc tctgtctg 540
tccggcaccc gggcgctgg tccgtggcc tggacgagt ccaatgcga ggagccagg 600
aaccggcccg ggagcatgtg gcagggcg 660
ggaaacgaga gtcggcg 720
tgtgtatcc gccccccgtt 780
gaagatgaga actggactga tgaccaactg ctgggttta aacccatgcaaa tgaaaacctt 840
attgtggct gcaataataat 890
aattccctt aatttccaaatg tcaaggatatg tgcgtttagt ctggatggaa aattgaagaa 960
gagaagccag attgtccaa gggccgtgt 1020
gattctgttc tgatcgaggg ttatgtctt 1080
tgcgtgtca acccccgagg ctgtctgc 1140
ctagtgtcaa aagccctcagg 1200
gttttcggcg tggactgcag 1260
ccggacagct atgaaactact 1320
agatcgaggt gtctctgtt 1380
35 cgcataatgtct ctcgtggca 1440
aatgatacaa agccagccctg 1500
cgaatggaca actgtcggtt 1560
cagtgtgtg agataaaactg 1620
tgtgaagatc cagtgtatcc 1680
cttggccacg gaggccgg 1740
40 gaacggccact gcttcgc 1800
ggggaggtttt gcccgtgt 1860
ggggagttat caaactgcac 1920
cacaatggtt gtcggacctg 1980
caaggctgca cttgtactg 2040
tgtgagtgtt gcccggcc 2100
cttggattgtc tgaagaataa 2160
ctctcatgtc gtaagatctg 2220
tgcaagtgtca gagaggccctc 2280
accgtggatg gtcatcatca 2340
tactgtctca atggacggga 2400
50 aaccccaacca ttcaccctgg 2460
aaggccagac tcaagtgtc 2520
ggagaaacgt ggaacattga 2580
tgtgagacag aggtgtgtcc 2640
tgctgcccac agtgtacaga 2700
cctaattact gaaaaatga 2760
gacgttgta ccagctgcat 2820
55 ccttcgtat ctcgtgaaag 2880
aaagacacaa ttccaaagaa 2940
ggtgggtgtc cacttcagtg ggaaggccct 2940
tgccgacgag

cccdlyeckpv	fgvdcrtrvec	ptvqqtacpp	dsyetcqrvt	adgcctlptr	ceclsglcgf	300
pvcevgstpr	ivsrgdgtpg	kccdvfecvn	dtkpacfvnn	veyydgdmfr	mdncrfcrqc	360
ggvaicftaq	cgeinceryy	vpegeccpvc	edpvvpfnnp	agcyanglil	ahgdrwredd	420
ctfcqcvng	rhcvatvcvgq	tctnvpkvpg	eccpvceep	iitvdppacg	elsnctlitr	480
dcingfkrdh	ngcrtcqcin	tgelcserkg	gctlncpfg	ltdaqnceic	ecrprpkkr	540
piicdkyckpl	gllknkhgcld	icrckkcpel	scskicplgf	qqdshgclic	kcreasasag	600
ppilsgtclt	vdghhhkknee	swhdgcrecy	clngremcal	itcpvpacgn	ptihpgqccp	660
scaddfvvqk	pelstpsich	apggeyfveg	etwnidscq	ctchsgrvlc	etevcppllc	720
qnpsrtqdsc	cpqctdqpf	pslsrnnsvp	nyckndegdi	flaaeswkpd	vctscicids	780
viscfsescp	svscerpvlr	kggccpycik	dtipkkvvch	fsgkayadee	rwldsdcthc	840
yclqqgtlcs	tvscspplpvc	epinvegsc	pmcpemvyp	ptnipiektn	hrgevdlevp	900
lwptpsendi	vhlprdmghl	qvdyrdnrlh	psedssldsi	asvvpviic	lsiiiaflfi	960
nnkkqkwipll	cwyrtptkps	slnnqlvsd	ckkgtrqvvd	ssqrmrlriae	pdarfsgfys	1020
mqkqnhlqad	nfyqtv					

15 <210> 35
<211> 716
<212> DNA
<213> Human

20 <400> 35

```

cgatgtacccgt gagggttcgtt cggggggaaa ggcggccggg cccttgcgttc .cgggggcgtc 60
acccggggct cctggggccgc tctggccggc tggggctgtgg cagcgatctt gctttgtccc 120
agaagttccag agggatcagc cccagaacac acccttcctcc cccggggacgc gcagctttct 180
ggaggctgtgg gaaggcatgaa agagtgggtt ccacctgtgg gccgactgtgg aaaagaattt 240
ccagaactcg gtcctatttt acagatttaggaa aactatgggt tcaagaagag aggacggggc 300
ttgaggaaat ctcctgttcc tccttatatgg aactcaaaat gaccataactt aacagtgttag 360
aaggctttttt taaggctcta aatgttcagggtt tctccatcc cctgtatgcct gacttgtaca 420
gtcactgtgg agtagacgggtt ttccctccacc cagggttgc tcagggggtt gatctgggtc 480
ccatcttgcgtt cttaaagacc caaacaagggttttttccaggatctt ggagcctcta 540
tctgggttagt gtcgtaaacctt ctgtgtgcctt cccgttaccctt catctgtccca gtgactgttag 600
cccccatccca cctaaacagggtt tgcccacagg gattactgtgg ggttaagacc tttagaacttgg 660
gtctagcacc cgataaaggcc tcaataaaatgggttccctt ccacatcaaa aaaaaaa

```

35. **<212> DNA**
<213> Human

<400> 36

50 <400> 37

ccctcgagcg ggcgcgggg caggtacttt taccaccaa ttgttcactt gactttaaga 60
aaccctaaaa gctgcctggc tttcagcaac aggccatatac acaccatggt gagtctccat 120
aagggacacc gtgt

55 <210> 38
<211> 644
<212> DNA

<213> Human

<400> 38

5	aaggcctgttgc	tcatggggga	gggtggggcg	cttggggcc	actggcgccc	gaggtagagg	60
	cagtggcgct	ttagttggtc	gggggcagcg	gcagatttga	ggcttaagca	acttcttcgg	120
	gggaagagtg	ccagtgcagc	caactgttaca	attcaagatc	tttatctata	tccatagatt	180
	ggaatattgg	tggccagca	atcctcagac	gcctactta	ggacaaatga	ggaaaacttag	240
	gcttggtgaa	gttacgaaac	ttgtccaaaa	tcacacaaact	tgttaaaggc	acagccaaga	300
10	ttcagagcca	ggctgtaaaa	attaaaaatga	acaaaattacg	gcaaaagtttt	aggagaaaaga	360
	aggatgttta	tgttccagag	gccaggctgtc	cacatcatgtg	gcagacagat	gaagaaggccg	420
	ttcgcacccgg	aaaatgttagc	ttcccggttgc	agatccctgg	ccatgttagaa	gtttagatgt	480
	caagagaat	gcacatctgt	gaagatgtgc	taaaaagatt	gaaagctgtt	aggaagtctt	540
	tcaaaggctt	ctttggaaaa	actggaaaga	aaggcgttta	agcagtttct	gtgggtctaa	600
	gcagatggac	tcaagagggttgc	tggatgaaaa	actaaggacc	tcat		

15 <210> 39
<211> 657
<212> DNA
<213> Human

<400> 39

25	ctttttgttt	gggtttcca	atgttagatgt	ctcagtgaaa	tgtgcagata	tactttgttc	60
	cttataatgg	caccagtgtt	aattatggac	aaatacatta	aaacaagggt	tcctggccca	120
	gcctcccatc	taatctctt	gataactctt	gaatctaagt	ctgaggagcg	atttctgaat	180
	tagccagtgt	tgtaccaact	ttctgttagg	aattgttatta	gaataacctt	tctttttcag	240
	acctgctcag	tgagacatct	tggggatgaa	agtagggaaa	tagacatttgc	gtggaaaaac	300
	agccaaatga	gaacattaaa	aagacttcat	caagtatgag	tataaaaggc	atggaaattc	360
	tggcccttgc	agccaaatga	gaagaaaaaaaa	ttctgttcag	cagtttccac	tgtgttaaga	420
	ttttttgttt	tttacacgca	tggaaaaatgt	atgtgttaagt	ggttatagatt	ttaatcagct	480
	aacagtca	ccagagattt	tgatcagcac	caattccat	agtagtaagt	atttaaaagt	540
	taagaatatac	tactacattt	aacattataa	agtagagttc	tggacataac	tggaaaattag	600
30	atgtttgttt	caatagaaaat	ttgttcccac	ttgttattttc	aaacaaaatta	tcggaaac	

<210> 40
<211> 1328
<212> DNA
<213> Human

35 <400> 40

40	acaattttaa aataactagc	aattaatcac agcatatcg	aaaaaaagtc acagtggat	60
	ctggtagtt tttaggct	cattatgggt agggtcgtt	agatgtatata aagaacctac	120
	ctatcatgct gtatgtatca	ctcattccat ttcatgttc	catgcatact cgggcatact	180
	gctaatatgt atccctttaa	gcactctcaa ggaaacaaaa	ggccctttaa ttttataaaa	240
	ggtaaaaaaa atccccaaa	tatttgcac tgaatgttac	aaagggtgaag ggacattaca	300
	atatgactaa cagcaactcc	atcaacttgg aagtataata	gaaaatagct tctaaatcaa	360
	actcccttca cagttccgt	tctaccacta caaggactgt	gcatctaaatg aataattttt	420
	taagatttac tataatgttat	agttatgtatat	gcatttattt aaaaatgcatt	agactctt 480
	ccatccatca aatactttac	aggatggcat ttaatacaga	tatttcgat ttcccccaact	540
	gctttttatt tgtacagcat	cattaaacac taagctcagt	taaggagcca tcagcaacac	600
	tgaagagatc agtagtaaga	attccatttt ccctcatcg	tgaagacacc acaaattgaa	660
	actcagaact atatttctaa	gcctgcattt tcactgtatgc	ataattttct tagtaatatt	720
	aagagacagt tttctatgg	catctccaaa actgcatgc	atcaactatgc ttactctgc	780
	ttaattttat gagaaggat	tcttcatttt aattgtttt	ggattactc cacatcttg	840
	tttattttt gactaatcg	atttcaataa gagttaagtt	aaattggggg tcataaaagc	900
	attggattga catatggttt	gccagccat gggtttacag	gcattgcccc aacatttctt	960
	tgagatctat atttataagc	agccatggaa ttccatttat	ggatgttgg caatcttaca	1020
	ttttatagag gtcataatgc	tagtttcat aggtgtttt	taagaactgta ttgctctct	1080
	gtgagttaaag ctatgttac	tactgggacc ctcagagga	ataccacta tgttacactc	1140
	ctgcactaaa ggcacgtact	gcagtgtgaa gaaatgttct	gaaaagggt tatagaatc	1200
	tggaaaataag aaaaagag	ctctctgtat tctataattt	gaagagaaaaaa aagaaaaaac	1260
	ttttaactgg aaatgttagt	ttgtacttat tgatcatgaa	tacaagtata tattaattt	1320
55	tgaaaaaaa			

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

aacagagact ggcacaggac ctcttcattt caggaagatg gtagtgttagg caggtaacat 60
 tgaaccttt tcaaaaaagg agagctttc ttcaagatataa ggaagtggta gttatgggtt 120
 taaccccccgg ctatcagttc ggatgggtgc cacccttcct gctgttaggt ggaagcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
 tgggttctacc tcttccttgc tcctttgttt aaaggcctgg ctgggagct tcctttggg 300
 tgccttcctc ttctccaacc aacagaaaag actgtcttc aaaggtggag ggtcttcatg 360
 aaacacagct gccaggaggcc caggcacagg gctgggggccc tgaaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgtt ggctttaccc aaggctcga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtccctg gcccattttt gacagatggc gggacggaaa 540
 tgcataagac cagcctgcataa gaaagacatg tgtttgtatg acaggcagtg tggccgggtg 600
 gaacaacac aggccttggta atccatggta ctgaatcaga acccttagggc tgccatctgt 660
 cagccgggtg acctgggttca attttagctt ctaaaaggctt cagtctccat atctgcaaaa 720
 tgaggcttgc tatacctgtt ttgaagggtt gctgagaaaa tttaagataa gggtatccaa 780
 aatagtctac ggcataccca ccctgaacgt gcctaatctc gtaagctaag cagggtcagg 840
 cctggtagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
 actctgtttt aacagtagcg tggcacacag aaggcactca gtaaataactt gttgaataaa 960
 tgaagtagcg atttgggtgtt aaaaaaaaaa

<210> 42
 <211> 956
 <212> DNA
 <213> Human

25

<400> 42

cggacgggtgg ggcggacgcg tgggtgcagg agcagggcggtt ctggccactg ccccaaccaa 60
 ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 ttgcctgtct aaaggcttaa ctaagactcc cgcccccggc tggccctgtg cagacccatcc 180
 tcaggggatgtt tttacctgtt gctcgggaag ggaggggaag gggccggggaa gggggcacgg 240
 caggcgtgtg gcagccacac gcaggccggcc agggccggca gggacccaaa gcaggatgac 300
 cacgcaccc caccgcactg cctcccccaatgcattttgg aacccaaagt taaactgagc 360
 tcgcagcccc cgcgccttcc ctccgcctcc catccccgtt agcgctctgg acagatggac 420
 gcaggccctg tccagcccccc agtgcgtcg ttccgggtcc cacagactgc cccagccaaac 480
 gagattgtgtt gaaaaacaaatg caggccagggtt gggccggacaa aaggggccagg tgcggccctgg 540
 ggggaacggta tgctccgagg actggactgt tttttcaca catcggttgc gcagggtgg 600
 gaaggaaagg cagatgtaaa tttatgttttgg gtttacaggg tatatttttgc atacccatcaa 660
 tgaattaattt cagatgtttt acgcaaggaa ggacttaccc agtattactg ctgtgtgtct 720
 ttgtatctct gtttacccgtt caagaggcgtt gtgcaggccg acagtccgtt accccatcac 780
 tcgcaggacc aaggggccgggg ggactgttcc ctcacgcctt gctgtgtctt ccctccctc 840
 cctcccttgg gcagaatgaa ttgcgtatgtt attctgttgc cgccatctgc gcagggtgg 900
 ggtattctgtt catttacaca cgtcgatcttca attaaaaaagg gaattataactt cccaaaa

<210> 43
 <211> 536
 <212> DNA
 <213> Human

45

<400> 43

aaataaaacac ttccataaca ttttgggtttt gaaatgttattt aatgcataatcc cacttttttc 60
 cccctagttt ctaaatgtt aagagagggg aaaaaaggctt caggatgtt ttcacccatcc 120
 agtgttagttt gtctttttttt ttactcttgg aaatagagac tccattttgg ttttgacattt 180
 ttggaaaccctt agtttttacca ttgtgtcgtt aaaaacatataa gatagtttgc gaggcatatga 240
 tctaaataaa gacatgtt ggggttagttt gaaatctaaa agtaggttttgc agccaaatag 300
 cattctcatc ccttaacaga caaaaacttta ttgttcaaaa gaaatggaaaat aggtgaaaat 360
 attttttccaa gatggaaactt gtgcacttc caatttgcataatcataa aggagacaga 420
 ctggaaaaag tgggttatgtt cacctttaaa acccttctgtt gtaatatttttgc tggtagctaa 480
 aggtgggtttt ccccgccacc tggaccttgc cagtttttttgc tccgtgggtt accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

<400> 44

ggggggggac	gagtatggaa	ccctgaaggt	agcaagtcca	ggcaactggcc	tgaccatccg	60
gctccctggg	caccaagtcc	caggcaggag	cagctgttt	ccatcccttc	ccagacaagg	120
tctattttt	tcacaatgac	cttagagag	gtctcccaagg	ccagctcaag	gtgtcccaact	180
atcccctcg	gagggaaagag	gcaggaaaat	tctcccccggg	tccctgtcat	gtctactttct	240
ccatcccaagt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
gtgttttccc	ttagggccag	gactttgggg	tcacgtctat	ctgttccttc	ttggccccatt	360
catggcagg	tctgggctca	aagctgaact	ggggagagaa	gagatcaca	gctaccatgt	420
gactttacct	gattgcctc	agttttgggt	tgcttattgg	gaaagagaga	gacaaagagt	480
tacttgttac	ggaaatatg	aaaagcatgg	ccagggatgc	tagaggagat	tctagcaggg	540
gacaggattt	gctcaatgt	ccccctgaggg	ctttcccaagt	cttggaaatgc	attccatgtat	600
atttaggaat	cggggggtggg	tgggtgtgggt	gggctagttt	gggttgaattt	tagggggccga	660
ttagcttggg	tacgttgagca	gggtgttaag	tttaggttctg	cctgttatttc	ttgttccctt	720
ggaaatgtcc	cctttttcag	tgcagacct	cagtcccaagt	gtccatatcg	tgcccagaaa	780
agtagacatt	atccctcccc	atcccttcc	cagtgcactt	tgacttgcgt	agtgccttgg	840
gccccagtgtac	ctggggggagc	ctggctgcag	gcccctactt	gttccctaaa	ccttgggtggc	900
tgtgatttcag	gtcccccagg	gggacttcagg	gaggaatatg	gctgagttct	gtagtttccca	960
gagttggctg	gtagagcctt	ctagaggttt	agaatattag	cttcaggatc	agctgggggt	1020
atggaaatttg	ctgaggatca	aacgtatgtt	ggtaaaagga	taccaggatc	ttgctaaagg	1080
tgagggacag	tttttttttgg	ggacttacca	gggtgtatgtt	agatctggaa	cccccaagtg	1140
aggctggagg	gagttaaagg	cagtatggaa	gatagggtt	ggacagggtt	ctttggaaatg	1200
aaagagtgtac	cttagagggc	tcccttggcc	tcagaaatgc	tcctgtctgt	gtaaagatga	1260
gaaggtgtct	ttactcgtt	aatgtatgagt	gactatattt	accaaagccc	ctacactgtct	1320
ctgggtccct	tgttagcacag	gagactgggg	ctaaggggcc	ctcccaaggga	agggacacca	1380
tcaggccctt	ggctgaggca	gtagcataga	ggatccattt	ctacactgtat	ttcccagagg	1440
actagcagga	ggcagccctt	agaaaccggc	agttcccaag	ccagcgctt	gtgtttctct	1500
cattgtactc	ggccctctcc	caacctctcc	tctaaccac	tagagattgc	ctgtgtccctg	1560
cctctgtcc	ctttagaaat	gcagctctgg	ccctcaataa	atgccttctg	cattcatctg	1620
aaaaaaaaaa						

<210> 45
<211> 169
<212> DNA
<213> Human

<400> 45
tcttttgctt tttagctttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggt ttatgatctt cagtctgatt ccagtgcgtc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagttga

<210> 46
<211> 769
<212> DNA
<213> Human

<400> 46

tgcgggtcat	atttactatc	ggcaataaaa	ggaagcaaaag	cagtattaag	cagcgggtgg	60
atttgcgt	ttcactttt	ataaaagtgt	acataaaaatg	tcatatttcc	aaatttaaaa	120
acataactcc	agttcttacc	atgagaacag	catggtgatc	acgaaggatc	ttcttgaaaa	180
aaacaaaaaaac	aaaaacaaaaa	aacaatgatc	tcttcgttgt	atcacatcaa	atgagataca	240
aaagggtact	aggcaatctt	agagatctgg	caacttattt	tatataatag	gcatctgtga	300
ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaaatgtat	taaatgcaag	360
cttcatataa	tgacaccaat	gtctctaagt	tgctcagaga	tcttgactgg	ctgtggccct	420
ggccagctcc	tttcctgata	gtctgattct	gccttcata	ataggcagct	cctgatcatc	480
catggccatg	aatgaaaaaa	caagcatgga	atataataac	tttaacatta	aaaaatgttt	540
tattttgtaa	taaaaatca	tttccccattt	aaaccttcaa	aaactttgca	gaatgagggt	600
ttgtatata	tgtacaaatg	gtaccttctt	agtcaagaa	aacatcatta	tttctgtctg	660
cctgcctttt	tgtttttaaa	aatgaagact	atattgaaa	caagtttgc	ttcagtatca	720

ggacatgttg acggagagga aaggttaggaa agggttaggg atagaagcc

<210> 47
<211> 2529
<212> DNA
<213> Human

<400> 47

ttagttcat	agtaatgtaa	aaccatttgt	ttaattctaa	atcaaatcac	tttcacaaca	60
gtaaaatta	gtgactgggt	aagggtgtcc	actgtacata	tcatcatttt	ctgactgggg	120
tcaggacctg	gtcctagtcc	acaagggtgg	caggaggagg	gtggaggcta	agaacacaga	180
aaacacacaa	aagaaggaa	actgccttgc	gcagaaggat	gaggtggtga	gcttgcgcag	240
ggatggtggg	aagggggctc	ccgttgggg	ccgagccagg	agtccaaagt	cagctctcc	300
gcctactta	gctccctggca	gagggtgagt	ggggacccat	gagggtcaaa	atcaaatggc	360
atttggccag	cctggctta	ctaacagggtt	cccagatgc	ctctgttgc	ttagctctc	420
tgggctca	ccatttcat	gaagagttca	aatgattcat	tttcttaccc	acaactttt	480
attattcttc	tggaaaccca	tttctgttga	gtccatctga	cctaagtctt	ctctccctcc	540
actagttggg	gccactgcac	tgaggggggt	cccaccaatt	ctctctagag	aagagacact	600
ccagaggccc	ctgcaacttt	gcccatttcc	agaaggtat	aaaagagca	ctcttgagt	660
ggtgcccaagg	aatgtttaaa	atctatcagg	cacactataa	agctgtgtt	tttttccctac	720
caagtggatt	ccggcatatga	accacactt	caactactt	tattttgtct	gtttaaaacac	780
tgaatctgg	tgttgcacagg	tacaaaggag	aagagatggg	gactgtgaag	agggggggggc	840
ttcccttcatc	ttccctcaaga	tctttgttcc	cataaaactt	cgactatata	ttgagaaaaaa	900
gcaatagatg	gggcttccta	ccatttggtg	gttattgtct	gggttagcca	ggagcagtgt	960
ggatggcaaa	gttaggagaga	ggcccagagg	aaagcccatc	tccctccagc	tttggggctt	1020
ccagaaagag	gctggatttc	tggatgaag	cctagaaggc	agagaagaaa	ctgttccacc	1080
aggtgaacag	tcctacactgc	tttgttaccat	agtcctctaa	taagattcag	aggaagaagc	1140
ttatgaaact	gaaaatcaaa	tcaaggtatt	gggaagaata	atttcccttc	gattccacag	1200
gagggaaagac	cacacaaat	cattgtgtct	gggtccccc	aggccctgcc	acctggctt	1260
acaatccat	aggggttgc	tgttggcag	ctacatgtt	ccctgttgg	acacacata	1320
caaggatgtt	tccaggaaact	ctatacgaac	ataccaaaat	cagggtcaca	tgtggggttc	1380
ccctttccctt	gcctttcat	aaaagacaac	ttggcttctg	aggatggtgg	tctttgcat	1440
gcagttgggc	tgacctgaca	aagccccccag	tttcctgtgg	caggttctgg	gagaggatgc	1500
attcaagctt	ctgcagccta	ggggacagg	ctgttgttc	agttattact	gcctcgagc	1560
tccaaatccc	accaaagtcc	tgacttccagg	tctttcttaa	tgacacagtag	tcaagtctca	1620
cttcggca	attctcggct	gtatgttctc	tggcagagag	aggcagatga	acatagttt	1680
agggagaaag	ctgatgggaa	acctgtgagt	taagccacat	gtctcaccag	gaataatatt	1740
tgcaggaaaa	ccaggaagtc	atctcaagg	ttctctgagg	ccaaagacac	tgagccacagc	1800
ccagggccaa	ttaaaatct	ttgatgtct	ggtgaatca	ccaaatgtacc	ccagctttag	1860
ctactgcaat	tatgatttt	atgggacagc	aatttctgc	atcttacag	aggaagaaga	1920
ggggggatgg	gaggggaagg	aaagagaaca	gagcggcact	gggatttgaa	aggggaacct	1980
ctctatctga	ggagccccca	ctggcttcag	aagcaactt	ccaaagggtt	ttaaaagaca	2040
tggaaaatttc	cagaatattcc	atttggtgca	tccctttgtt	tctgtatata	taaactcagg	2100
tggaaaattata	ctctgacat	tttcttctt	ctgccttc	cctctgtcaga	gtcaggacat	2160
gcagaactgg	ctgaaacaag	attctatgtt	gtcacccat	agagatgact	caatgtccaa	2220
gcctgaaatgtt	atagatgtt	tacagcgtgt	gcatatttca	ggggcatatcg	ccaaactggtc	2280
tccggatcc	aagctctgtat	gaagaaacaa	gactccttga	tgtttaactg	atccctactga	2340
ttccaggagt	caagatttgc	caggaagcc	aacaccagga	gttgggggtgg	cacgtcacc	2400
gtccagagcc	ctgcccacgg	tgtacgcagg	agcccagcat	taggaatca	ggagccagaa	2460
catgatcacc	agggccacaa	ataggaagag	gcgtgacagg	aactgtctgt	ccacatacatct	2520

<210> 48
<211> 1553
<212> DNA
<213> Human

<400> 48

tttttttttt	tttttgcattt	ctgggacaat	taagctttat	ttttcatata	tatataatatatt	60
ttcataatata	tatatacata	catataaaaa	ggaaacaattt	tgcaaaattt	cacacctgac	120
aaaaccatat	atacacacat	atgtatgcatt	acacacagac	agacacacac	acccgaagct	180
ctagccaggc	ccgttttcca	tccctaaga	ccatcttc	atttggcccc	ttcttagggtt	240
ggggccctga	gcttggttgc	tagaagtttgc	gtctaatat	aaccatagct	ttaatcccca	300
tgaaggacag	tgttagacctc	atctttgtct	gctccccgct	gcctttcagt	tttacgtgat	360

EP 1 586 333 A2

5 ccatcaagag ggctatggga gccaagtcaa cacggggat tgaggcta at tcacctgaac 420
 tcgaaaacag cgcccaagctt cctcaccgca ggacacgcgc ttttctttt ttttcctcga 480
 gacggagct cgctgtgtt cccaggctgg agtgcagtgg cacggctcg gctcaactgca 540
 agctccacct cctggattca taccatctc ctgcttcagc cttccagata gctggacta 600
 tagtgccaa ccactaacgcc tagtaattt tttttgtat ttttagtaga gacagggtt 660
 caccgtgtta gcccaggatgg tctcgtctg actttgtat ccgcggcctt cggccctccca 720
 aagtgcgtggg attacaggcg tgagccacca caccctggcc cggcacgtat ctttaagga 780
 atgacaccag ttccctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgtctc 900
 10 cgagcggggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcgtgg tgcacctgg tgggtggaaagc cagcccttgg ggcaggaaac cagctcagag 1020
 agcttaccca gtcgtcgtc tggcaggagc cagttatcc cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctctt cccgcgtggg agactggggc tccttgctt 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactgtt ccctgaaaag cgggccttgc 1200
 agggccaagt gagggtctca ggtccaaac ccagtggcc tctgaaaggg ggtgtcagg 1260
 15 cgagggggcagg aggaggcttc tctcttagtcc cttggaggg tttggcttag agaagagtga 1320
 gcaggggact gggaaatggtc caggcaggga agggagctga agtgtatttgg ggtaatgtcc 1380
 tcagatcgat gtatttctct cctgttctc ccggagccct cttgtcaccg ctgtccct 1440
 gcaggaggcc catctcttctt gggaggttat ctgacttaac ttcaactaca agttcgctt 1500
 tacgagaccg ggggttagcgt gatctccctgc ttccctgagc gcctgcacgg cag

 20 <210> 49
 <211> 921
 <212> DNA
 <213> Human

 <400> 49

 25 ctgtggtccc agctactca gaggctgagg cgggaggatt gcttgagccc aggagttgg 60
 tggtcagtg agccaagatc gcaccattgc cttccactt gggccacgg gcaataaccct 120
 gtcctcggaaa acaaacaaca aaaagcagaa acgtgtggg ggtcggtt cgggaaaacc 180
 gctgtcaga acacttggct actcttccca cagatcgtg gacctgggaa tgagggtttg 240
 tccctggagg cttttctcca cttgttgcc accagaccgg ccatggaaac cttggccaca 300
 gaagcctccc gggggagttag ccagagctg gaccgctgt ctgtatgtc tgggggtggag 360
 30 ggagggtggg gagggtgtcaa ggggtgtgt gtccccgggg ggtgttcatg gcaagcatg 420
 tgcgtgcctg tgggtgtcg tgcccttccc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ctttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaagggggac accctttccct ggacctgggg gtctcgccgt atctcatgac 600
 caggtctaa atgaccggac atgcattacc tgcccttcga tgaccaaccc cccctgtcccc 660
 35 gtcccgtga cttggggcccttggcgttca cgggtatgcc tgctcctgac attgggtttc 720
 actgttagcaa actacatttc ggatggaaat ttcatgtac atgtgtggca tggaaaat 780
 ttcaaataaa atggacttga tttagaaaagc caaaaagctg tgggtcctt ccagcacgg 840
 tactttgacc ttttgcctac aacccttcc ttgggtccga ggctggtagc ttgttcaact 900
 tcagatgggtt gggggcggggtt g

 40 <210> 50
 <211> 338
 <212> DNA
 <213> Human

 <400> 50

 45 atgatctatc tagatggccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tccctccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaattt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagtacc acccctcagt 180
 aacgacctag cttgggtaga aacaaatgtc agcatgatac cataactcaat gatcctcgt 240
 cactgttgc attgtcatca ttccatggcc ttactttccc tctcagcggcc atttgctaca 300
 50 gtaaaaaact ttctttcttg aattctgtt tctcttgg

 <210> 51
 <211> 1191
 <212> DNA
 <213> Human

 55 <400> 51

5 cgaccggcca ctactgttt tctttgaccc ttccagttt gaagataaag agggaaataat 660
ttctctgaag tacttgataa aatttccaaa caaaacacat gtcacttca ctgataaaaa 720
atttaccgca gtttggcacc taagagtatg acaacagcaa taaaagtaa tttcaagag 780
ttaagattt ttcagcaaaa tagatgattc acatttca gtccttttgg aaatcagttt 840
ttaatattt tcttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
ttttttttt ttgcgagatg gaatctcgct ctgtcgccca gccccggatgtc actggcgaa 960
gcccggctca ccgcaatctc tgccaccccg

10 <210> 54
<211> 250
<212> DNA
<213> Human

<400> 54

15 catttccca ttggtcctga tggtaagat ttagttaaag aggctgttcaag tcaggttca 60
gcagaggctt ctacaagaag taggaaatca agtccctcac atgggttattt aaaaacttagt 120
agtgggtggag tagtggaaaaaa gaaatctgag caacttcata acgttaactgtc ctttcaggg 180
aaaggccatt ctttaggaac tgcattctggt aaccacacc ttgatccaag agcttagggaa 240
acttcagttt

20 <210> 55
<211> 2270
<212> DNA
<213> Human

<400> 55

25 gcccggccca gcaagcgcccc cgccctccgc gccttctccg ccgggaccc gaggcggaa 60
ggccggcgcc cccggcccgcc ctcgcctccc tgccccccgg gcacaccggc cggccacccc 120
gaccggcgcc cgcaacggccgt gtcgcgtca caccagcttgg tggcgctt cgtgcggcg 180
ctggcccccgg gctacttccgt cgcccaacaa tgagctcccg catcgccagg gcgctcgcc 240
tagtcgtcac ccttctccac ttgaccaggc tggcgctctc caccctggccc gtcgcgtcc 300
actggccctt ggaggcgccc aagtgcgcg cgggagtcgg gctggccgg gacggctcg 360
gctgtgtaa ggtctcgcc accacacaa ggggtggaa tgcaacttccg gcccaacatc caccgtctcg 420
gcagagctca gtcaagaggc aaggtttcca gcccaactgtt aacacatca gcaatctc aaggggatct 480
aaatataactc aagggatctc agaccctgtt aatataactc cagaatctc caaaacgggg 540
ttccctgtgt tcccaagaaa tcaaaagttaac cgggcgtgtc ccatggaggcc ccgttccgtt 600
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccgagggtgg 660
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccgagggtgg 720
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccgagggtgg 780
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccgagggtgg 840
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccgagggtgg 900
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 960
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1020
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1080
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1140
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1200
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1260
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1320
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1380
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1440
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1500
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1560
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1620
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1680
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1740
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1800
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1860
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1920
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 1980
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 2040
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 2100
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 2160
tttgcggaggat gggctgttgc cccatgttgc aggactgtgg attcgatgtc tccacacgg 2220

<210> 56
<211> 1636
<212> DNA
<213> Human

<400> 56

cttgaatgaa	gctgacacca	agaaccgcgg	gaagagcttg	ggcccaaagc	aggaaaggga	60
agcgctcgag	ttggaaagga	accgctgctg	ctggccgaac	tcaagcccg	gcgc(cc)ccac	120
cagtttGatt	ggaagtccag	ctgtgaaacc	tggagcgtcg	ccttctcccc	agatggctcc	180
tggtttgcT	ggtctcaagg	acactgcatt	gtcaaaactga	tccccctggcc	gttggaggag	240
cagtccatc	ctaaagggtt	tgaaagccaa	agccgaagta	gcaaaaatga	gacgaaaggg	300
cggggcagcc	caaaagagaa	gacgctggac	tgtgttceaga	ttgtctgggg	gtggccttc	360
agcccgtggc	cttccccacc	cagcagggaa	ctctggccac	gcaccacccc	ccaagtgc	420
gatgtctctt	gcctgggtct	tgctacggga	ctcaacgatg	ggcagatcaa	gatctgggag	480
gtgcagacag	ggctctgtct	tttgaatctt	tcgggcccacc	aagatgtcgt	gagagatctg	540
agcttcacac	ccagtgccag	tttgattttt	gtctccgcgt	cacggataa	gactcttcgc	600
atctgggacc	tgaataaaca	cggtaaacag	attcaagtgt	tatccggccca	cctgcagtgg	660
gtttactgt	gttccatctc	cccgactg	agcatgtgt	gctctgcgc	ttggagagaag	720
tcgggttttc	tatgggcat	gaggctctac	acgtttaatc	ggaagctaga	ggccatcaa	780
agcagtgttg	tctcttgtga	cttctcccccc	gactctgccc	tgcttgtcac	ggcttcttac	840
gataccaaatg	tgatttatgtg	ggacccttac	accggcgaaa	ggctgaggc	actccaccac	900
acccaggtt	accccgcctat	ggatgacagt	gacgtccaca	ttagctca	gagatctgt	960
tgcttcttc	cagaaggctt	gtaccttgcc	acggtggcag	atgacagact	cctcaggatc	1020
tggggccctgg	aactggaaaac	tcctcatgca	tttgcctcta	tgaccaatgg	gttgcgtc	1080
acatctttt	cacatggtg	agtcttgcc	acagggacaa	gagatggcca	cgtccagg	1140
tggacagtc	ctagggtctt	gtcctactg	aagcttactt	gcggaaaggc	ctttcgaatg	1200
ttccctaaca	cttaccaagt	cctagactg	ccaatccca	aaagaaatgaa	agatgtcc	1260
acatacagga	cttttaaagc	aacaccacat	cttgcgttc	tttgcgtc	gttaaatcg	1320
cctgtcaaaag	ggagttgctg	gaataatggg	ccaaacatct	ggtcttgc	tgaatagca	1380
tttctttggg	attgtgaaata	gaatgttagca	aaaccagatt	ccagtgtaca	taaaagaatt	1440
tttttgtctt	taataatagata	caaatgtctt	tcaactttaa	tcaagttgt	acttatattg	1500
aagacaattt	gatacataat	aaaaaaattat	gacaatgtcc	tggggaaaaaa	aaaatgtaga	1560
aagatggtga	agggtgggat	ggatgaggag	cgtgtgc	ggggcctgca	gcgggttggg	1620
gaccctgtc	tgcgtt					

<210> 57
<211> 460
<212> DNA
<213> Human

<400> 57

ccatgtgtgt	atgagagaga	gagagattgg	gaggggagg	gagctacta	gcgcataatgt	60
gcctccagg	ggctgcagat	gtgtctgagg	gtgagcctgg	tgaaagagaa	gacaaaagaa	120
tggaatgagc	taaagcagcc	gcctgggggt	ggaggcccag	cccatttcta	tgccagcagg	180
ggcaggagcc	cagcaaggga	gcctccattc	ccaggactct	ggagggagct	gagaccatcc	240
atggcccgag	agccccccct	cacactccat	cctgtccagc	cctaatttgt	cagggtggga	300
aactggagct	ggaaatgcac	atagcaagtg	actggcagag	ctgggactgg	aacccaacca	360
gcctctttaga	ccacggttct	tcccaatcaat	ggaatgtct	agactccagc	cagggtggta	420
ccqagctcga	attcgtataatc	atggtcataatg	cttotttcttg			

<210> 58
<211> 1049
<212> DNA
<213> Human

<400> 58

atctgtacaa	gaatacctgc	cctggtaact	ctgcggatgt	ttctgtccac	ttgttcacat	60
tgaggaccaa	gatattcttt	tttacagagg	cacttgttcg	gtctaacaca	gacacctcca	120
tgacgacatg	ctggctcaca	ttttgcattt	ctgcagaagt	ccccctccca	gcctggacta	180
cagcagcact	ttcccccgtgg	ggtcgcattt	ccgtttcgcac	agagcctgga	gcactctgaa	240
tttcgtgtt	gtgcagggtt	taccctgggt	ctgcattctt	caggatttttt	aggttttttt	300
ggatctacaa	ttttgttagag	ttttccattt	tgagtctggg	tcatactttt	actgtttgtat	360

5 aaaatgtaaa cttcacctag ttcatcttct ccaaataccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtggtttt ctgcactg ctttgcaca 480
 ggacttgcg ggagagttag gaaattccca ttacgatctc caaacacgt a gcttccatac 540
 aatcttctg actggcagcc ccggatac aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcaatt tcataatctt tccccttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattt gaggctgaa acagtatcgt taaattgtat 720
 tttatatcg tggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 10 aacacttcgg ggggctgggt ggtgctgtt aagtgtgggt tgctcccttg tatgaaataa 840
 ggcacgttc acatgtctgtt gtccacatcc agccgttagca ctgagccctgt gaaatcactt 900
 aaccatcca ttcttccat ataccatgtt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt caggggccaaa gagcaggatgc cctccctt gctttctgtt gagttctgca 1020
 acttcaagaa agactctggc ttttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

<400> 59

20 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaacgtc 60
 ctttaattta caaaggctca gtcatttata cacatttaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt aaaaaaataa ttcatataaa 180
 gttgttcaca ctaggttctt agattaccag ctctgtgca aaaaaagaa atgaagaaaa 240
 atagatttat taacttagtat tggaaactaa ctttgcctt ggcttaaaac ctccctcactg 300
 25 ctcgctgtc ccacacaaaat gtttaagaag tcactgtcaat gtactccccg gctctgtatga 360
 aaagaagccc ctggcacaaaa agattccagt gcccctgaag aggctccctt cctccctgtgg 420
 gctctccctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctccggca gcaacggca gtggactcat ctgggtgatg gctgtatgt ctaacactgg 540
 ccaattcaat gccacaccta ctggttaccc tttgagggca ttctccaga cagaagcccc 600
 ttgaagccca ggtagggcag gatcagagat acacccgtgt ttgtctgaa gggctccaca 660
 30 gcccagtacg acatgtctgc agaagtatg tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc

35

Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGFNEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGFNEGF receptor systems.
- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGFNEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
 - a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - 20 c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGFNEGF receptor or Angiopoietin/Tie receptor systems,
 - 25 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 30 11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
 - g) compounds which inhibit receptor tyrosine kinase activity,
 - h) compounds which inhibit ligand binding to receptors,
 - i) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - 35 j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 40 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
- 45 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.
- 50 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

5

10

15

20

25

in which

r


n

R₃ und R₄

has the meaning of 0 to 2;

has the meaning of 0 to 2;

- a) each independently from each other have the meaning of lower alkyl,
- b) together form a bridge of general partial formula II,



35

wherein the binding is via the two terminal C-atoms, and

40


m

has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III

45

50



55

wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T₁ and T₄;

G

has the meaning of C₁-C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene

or C₃ -C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

5 Q has the meaning of lower alkyl, lower alkyloxy or halogene,


R₁ and R₂ independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

10 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N, N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygene atom, or a salt thereof,

20 and/or a compound of genaral formula IV




in which



40 A has the meaning of group =NR²,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,


Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



55 or A, Z and R¹ together form the group




20	m, n and o	has the meaning of 0 - 3,
	q	has the meaning of 1 - 6,
25	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/ or R _b together with R _c and or R _d or R _c together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
30	p	has the meaning of integer 1-4,
	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
35	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or C ₁₋₆ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R ⁵ and R ⁶ together form the group
	R ⁴ , R ⁵ , R ⁶ and R ⁷	



5

10

15




V,

in which

20

R¹ has the meaning of group


25



30

35


40


in which R⁵ is chloro, bromo or the group -OCH₃,

45

50

55

in which R⁷ is -CH₃ or chloro,




in which R^8 is -CH₃, fluoro, chloro or -CF₃

15 in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

20 R^2 has the meaning of pyridyl or the group



and

30 R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts.

35 16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the provisio that compound I is not identically to compound II.

40 18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

50 21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiobromoma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage

EP 1 586 333 A2

of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6